Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation

Dong,Zengxiang; Yao,Hong; Miao,Zhuangzhuang; Wang,Hao; Xie,Rongsheng; Wang,Ye; Shang,Yingfang; Gong,Chunlin; Liang,Zhaoguang

doi:10.3892/br.2017.896

Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation

Authors:
- Zengxiang Dong
- Hong Yao
- Zhuangzhuang Miao
- Hao Wang
- Rongsheng Xie
- Ye Wang
- Yingfang Shang
- Chunlin Gong
- Zhaoguang Liang
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: April 20, 2017 https://doi.org/10.3892/br.2017.896
Pages: 686-690

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess the efficacy and safety of the pharmacological conversion of persistent atrial fibrillation (AF) using amiodarone or/and ibutilide. Seventy‑nine consecutive patients (48 males and 31 females; mean age, 64.6±11.2 years; range, 40‑80 years) with non‑valvular chronic AF lasting >7 days (range, 7‑97 days) that were admitted to hospital for elective pharmacological cardioversion were randomly assigned to receive treatment with intravenous ibutilide (1 mg plus an additional 1 mg if required; n=39) or intravenous amiodarone (300 mg) plus intravenous ibutilide (1 mg; n=40). Success rates of cardioversion were 51.3% (20/39 patients) for ibutilide alone and 71.8% (28/39 patients) for amiodarone + ibutilide (P<0.05). A comparable increase in the QTc interval was observed in the two groups. It was observed that the co‑administration of amiodarone and ibutilide was safer than ibutilide alone with regard to the risk of ventricular arrhythmia. Forty‑eight patients of successful cardioversion were personally contacted for follow‑up. The result indicated that the sinus rhythm maintenance time of the amiodarone + ibutilide group (4.36±2.44 months) was significantly higher than that of the ibutilide group (2.34±1.75 months; P<0.01). In conclusion, pretreatment with intravenous amiodarone + ibutilide for pharmacological cardioversion of persistent AF is considered to be more effective and safer than treatment with ibutilide alone.

View Figures

View References

1	Waktare JE and Camm AJ: Atrial fibrillation begets trouble. Heart. 77:393–394. 1997. View Article : Google Scholar : PubMed/NCBI
2	Sasaki N, Watanabe I, Kogawa R, Sonoda K, Takahashi K, Okumura Y, Ohkubo K, Nakai T and Hirayama A: Effects of intravenous amiodarone and ibutilide on action potential duration and atrial conduction kinetics in patients with persistent atrial fibrillation. Int Heart J. 55:244–248. 2014. View Article : Google Scholar : PubMed/NCBI
3	European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, ; Camm AJ, Kirchof P, Lip GY, Schotten U, Savelieva I, Ernst S, van Gelder IC, Al-Attar N, et al: Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J. 31:2369–2429. 2010. View Article : Google Scholar : PubMed/NCBI
4	Workman AJ, Smith GL and Rankin AC: Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther. 131:221–241. 2011. View Article : Google Scholar : PubMed/NCBI
5	Vasić NR, Milenković BA, Pešut DP, Stević RS and Jovanović DM: Drug induced lung disease-amiodarone in focus. Med Pregl. 67:334–337. 2014. View Article : Google Scholar : PubMed/NCBI
6	Fadahunsi O and Krol R: Acute amiodarone pulmonary toxicity following lung resection. Int J Biomed Sci. 10:217–220. 2014.PubMed/NCBI
7	Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I and Bergmann JF: Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials. Arch Intern Med. 166:719–728. 2006. View Article : Google Scholar : PubMed/NCBI
8	Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L and Reynolds M: Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 13:329–345. 2011. View Article : Google Scholar : PubMed/NCBI
9	Camm J: Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits. Int J Cardiol. 155:362–371. 2012. View Article : Google Scholar : PubMed/NCBI
10	de Paola AA, Figueiredo E, Sesso R, Veloso HH and Nascimento LO: SOCES Investigators: Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation. Int J Cardiol. 88:157–166. 2003. View Article : Google Scholar : PubMed/NCBI
11	Korantzopoulos P, Kolettis TM, Papathanasiou A, Naka KK, Kolios P, Leontaridis I, Draganigos A, Katsouras CS and Goudevenos JA: Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation. Heart. 92:631–634. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kafkas NV, Patsilinakos SP, Mertzanos GA, Papageorgiou KI, Chaveles JI, Dagadaki OK and Kelesidis KM: Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol. 118:321–325. 2007. View Article : Google Scholar : PubMed/NCBI
13	Vos MA, Golitsyn SR, Stangl K, Ruda MY, van Wijk LV, Harry JD, Perry KT, Touboul P, Steinbeck G and Wellens HJ: Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. 79:568–575. 1998. View Article : Google Scholar : PubMed/NCBI
14	Fragakis N, Bikias A, Delithanasis I, Konstantinidou M, Liakopoulos N, Kozirakis M and Katsaris G: Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate. Europace. 11:70–74. 2009. View Article : Google Scholar : PubMed/NCBI
15	Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK and VanderLugt JT: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 94:1613–1621. 1996. View Article : Google Scholar : PubMed/NCBI
16	Yang T, Snyders DJ and Roden DM: Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K⁺ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation. 91:1799–1806. 1995. View Article : Google Scholar : PubMed/NCBI
17	Stambler BS, Beckman KJ, Kadish AH, Camm JA, Ellenbogen KA, Perry KT and VanderLugt JT: Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol. 80:458–463. 1997. View Article : Google Scholar : PubMed/NCBI
18	Gill J, Heel RC and Fitton A: Amiodarone: An overview of its pharmacological properties and review of its therapeutic use in cardiac arrhythmias. Drugs. 43:69–110. 1992. View Article : Google Scholar : PubMed/NCBI
19	Mitchell LB, Wyse DG, Gillis AM and Duff HJ: Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. Circulation. 80:34–42. 1989. View Article : Google Scholar : PubMed/NCBI
20	Stambler BS, Wood MA and Ellenbogen KA: Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiological determinants of enhanced conversion efficacy. Circulation. 96:4298–4306. 1997. View Article : Google Scholar : PubMed/NCBI